Drug maker Lupin on Wednesday said it has launched the generic version of Oracea capsules in the U.S. market. The company said it has launched the medication, indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea, following approval from the U.S. Food and Drug Administration.
As per the IQVIA MAT data, Doxycycline capsules (Oracea) had estimated annual sales of $128 million in the U.S.
Shares of the company were trading 0.77% up at Rs 1,617.35 apiece on Bombay Stock Exchange.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU

Government Raises Rs 1.42 Lakh Crore Via Asset Monetisation Till Fiscal 2025


No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod


Nagaland Governor La Ganesan Dies At 80


Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price — Here's Why
